Related Experiment Video
Updated: May 28, 2026
13:14
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Immunosuppressive monoclonal antibodies: current and next generation
D Focosi1, F Maggi, M Pistello
1U.O. Immuoematologia SSN, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. dfocosi@tin.it
Summary
Monoclonal antibodies (mAbs) are vital for treating cancers and autoimmune diseases but can increase opportunistic infections. Infectious disease specialists must understand risks associated with current and next-generation mAbs.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- Monoclonal antibodies (mAbs) are FDA-approved for various conditions including cancers, autoimmune diseases, and transplant rejection.
- While effective, mAbs are linked to a higher incidence of opportunistic infections.
Purpose of the Study:
- To review current and next-generation monoclonal antibodies.
- To highlight the infectious disease risks associated with these advanced therapies for specialists.
Main Methods:
- Literature review of monoclonal antibody therapies.
- Analysis of reported infectious complications associated with mAb use.
Main Results:
- Established mAbs improve patient survival in numerous conditions.
- Significant association between mAb therapy and increased opportunistic infections observed.
Conclusions:
- Infectious disease specialists need awareness of potential infections linked to mAbs.
- Understanding risks is crucial for managing patients on current and future mAb treatments.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:40Cell-mediated Immune Responses
Overview
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...